-The Telegraph New Delhi: The US Chamber of Commerce has advised its government to ratchet up pressure on India over intellectual property rights and prevent it from producing cheap generic versions of medicines under patent protection. In a recommendation to the United States Trade Representative (USTR), the chamber requested it to label India as a Priority Foreign Country, a tag which is given to the worst offenders of patent rights. The only...

-The United Nations With the deadline for the Millennium Development Goals (MDGs) looming, United Nations officials today called on countries to accelerate action to meet the global targets that have spurred the fastest reduction of poverty in human history. "With less than 830 days to go before the MDG target date, now is the time to accelerate progress - not give up," said the Administrator of the UN Development Programme (UNDP), Helen...

-The Economic Times Over a year ago, I had written a piece, Quo Vadis, Indian Pharma? (ET, May 11, 2012), in this column. Some key issues were highlighted in the article. Perhaps it is time to revisit the subject and bring out some current issues. Price control: Hurray, the department of pharmaceuticals has come out with a new non-intrusive price control methodology, moving from the cost-based model to the average market price...

-The Economic Times NEW DELHI: As patent wars heat up in the pharma space, mobile phone messages and Right to Information filings have emerged as potent weapons in the hands of multinationals keen to delay competition from low-cost generic versions of their patented products in India. Innovator drugmakers, who used to strike with patent suits after generic drugmakers released their versions in the market, have started gleaning information from text messages sent...

-The Business Standard USFDA's zero tolerance policy requires our drug firms to reorient not just processes but organisational cultures to serve that market credibly The following two quotes from the United States Food and Drug Administration (FDA) news releases may help put the Ranbaxy controversy in perspective. The first sums up what it is that drives the FDA and the second is typical of the challenge the pharmaceutical industry faces. (1) "The consent...